SCHEMBL30645895

SCHEMBL30645895

CCOC(=O)/C=C/c1cnc(OC)cc1N

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 2/20 0.49
FDPS P14324 1/20 0.44
MAOB P27338 1/20 0.43
CNKSR1 Q969H4 1/20 0.43
TTR P02766 1/20 0.41
CCNC P24863 5/20 0.41
CDK8 P49336 5/20 0.41
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA7 P43166 1/20 0.40
CA9 Q16790 1/20 0.40
CA14 Q9ULX7 1/20 0.40
NNMT P40261 1/20 0.40
CYP3A4 P08684 1/20 0.39
ESR1 P03372 1/20 0.39
P2RY12 Q9H244 1/20 0.38
MET P08581 1/20 0.38
CDK19 Q9BWU1 1/20 0.38
NPC1 O15118 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20439711 0.86 DPP4 (0.48) DPP4FDPSMAOBTTRCCNC
SCHEMBL29550737 0.86 DPP4 (0.48) DPP4FDPSMAOBTTRCCNC
SCHEMBL29673307 0.85 CNKSR1 (0.46) DPP4FDPSMAOBCNKSR1TTR
SCHEMBL30103131 0.85 CNKSR1 (0.46) DPP4FDPSMAOBCNKSR1TTR
SCHEMBL15507174 0.85 CNKSR1 (0.46) DPP4FDPSMAOBCNKSR1TTR
SCHEMBL23705853 0.85 CNKSR1 (0.46) DPP4FDPSMAOBCNKSR1TTR
SCHEMBL5371971 0.85 DPP4 (0.47) DPP4FDPSMAOBCNKSR1TTR
SCHEMBL5371975 0.85 DPP4 (0.47) DPP4FDPSMAOBCNKSR1TTR
SCHEMBL30908490 0.83 DPP4 (0.46) DPP4FDPSMAOBCNKSR1TTR
SCHEMBL29838567 0.83 DPP4 (0.45) DPP4FDPSMAOBCNKSR1TTR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260116891-A1 Oxazepin Derivative TEIJIN PHARMA LTD (JP) 2026-04-30 US disclosed
EP-4512811-A1 OXAZEPINE DERIVATIVE Teijin Pharma Limited (JP) 2025-02-26 EP disclosed
WO-2024130095-A9 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-08-02 WO disclosed
WO-2024130095-A1 COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF REGENTS OF THE UNIVERSITY OF MICHIGAN (US) 2024-06-20 WO disclosed
WO-2023204308-A1 OXAZEPINE DERIVATIVE 帝人ファーマ株式会社 2023-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260116891-A1 Oxazepin Derivative HCRTR2, HCRTR1, OXTR DPP4 1726/4885FDPS 4589/4885MAOB 622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.